nodamage
Joined 11 years ago
Joined 11 years ago
Some of us don't, so these types of universal proclamations are rather unhelpful.
Obviously offering add-ons to your own product is not the same as "showing ads" by any common understanding of the term.
Otherwise literally every app that offers a free version or trial with some form of paid upgrade would be considered "showing ads" because there's an upgrade button somewhere in the app.
If you're going to call that "showing ads" then I would argue you've overloaded the definition to the point where it becomes meaningless.
Alternatively, point the model at your git repo for platform A, read the diffs since release X and implement the same changes on platform B?
Until Apple developed it. Those early iPhones employed a lot of tricks to squeeze usability, battery life, and performance out of underpowered devices.
Prior smartphone attempts mostly applied PC-centric concepts to the device, it’s no surprise they ended up failing.
It's even worse than that, they appear not to have actually read the analysis they cited because two of the three studies on DXM found it was effective in adults. The same efficacy was not found in children but there are other very plausible explanations for this (difference in dosage and measurement techniques).
"Using objective and subject assessment tools validated in pediatric populations, this study provided evidence of the antitussive efficacy of DXM in children, aged 6–11 years, at the current OTC monograph dose and labeled indication. Compared with placebo, DXM treatment reduced cough rates 21.0% over 24 h (primary endpoint) and 25.5% during daytime/awake hours. In addition, children treated with DXM reported greater reductions in cough severity and frequency in the mornings and afternoons over 3 days than children treated with placebo. These treatment effects were statistically significant despite the study not reaching its planned sample size and are medically relevant."
Also as I mentioned in another comment, the author of original article misrepresents the findings of their own citation. DXM was found to be effective in adults, just not children.
The citation linked does not support this claim. In fact it suggests the opposite:
"Dextromethorphan was tested in three of the included studies (Lee 2000; Parvez 1996; Pavesi 2001). One report on a series of three successive studies on a total of 451 adults favoured dextromethorphan 30 mg given in a single dose to placebo in terms of cough counts (measured through cough acoustic signals using a microphone on the nose) and subjective visual analogue scales (Parvez 1996). Differences in mean changes of cough counts between active treatment and placebo varied from 19% to 36% (P value < 0.05) in the three studies (up to a net difference of eight to 10 coughing bouts every 30 minutes). This study did not report on side effects.
A study involving 44 participants tested a single 30 mg dose of dextromethorphan versus placebo (Lee 2000). Both treatment groups showed a decline in cough frequency (from 50 to 19 per 10‐minute period in the active treatment arm compared with 42 to 20.5 in the placebo arm, P value = 0.38 at 180 minutes follow‐up). Mean subjective cough scores showed a decline from 2.0 to 1.0 in the active treatment group compared to a decline from 2.0 to 1.5 in the placebo group (mean difference in decline in cough scores 0.5 at 180 minutes, P value = 0.08).
Pavesi and colleagues also tested a single 30 mg dose of dextromethorphan versus placebo (Pavesi 2001). Outcomes were measured through a three‐hour continuous cough recording, measuring cough bouts, cough components, cough effort, cough intensity and cough latency. Average treatment difference was 12% to 17% in favour of dextromethorphan for cough bouts (P value = 0.004), cough components (P value = 0.003) and cough effort (P value = 0.001), with an increase in cough latency (P value = 0.002)."
Two out of the three studies found DXM was effective in adults. The studies did not find the same efficacy in children but that could be due to differences in dosage (adult dosage is 30mg, child doses vary based on body weight) or in measurement techniques (as far as I can tell the child studies measured results via parental survey as opposed to more objective techniques like cough recordings).
For my projects I would say that the majority of the value an ORM delivers occurs after the query has returned from the database.
But for some reason everyone focuses on query generation as if it were the only feature of an ORM.
Maybe if you’re fetching data from a single table… once you start joining across multiple tables and need deduplicate your result rows it gets pretty annoying to do it by hand though.
If you don't actually need those features then obviously an ORM will offer less value to you. That doesn't mean ORMs aren't useful tools, they just aren't useful for the problems you work on.
I tend to work on projects where those features are useful and if the ORM didn't provide them out of the box then I would need to build them myself. In other words using a query builder alone does not adequately solve the problems I need to solve.